SCHEMBL24764426

SCHEMBL24764426

Clc1ncc2ccn(C3CCC4(CC3)OCCO4)c2n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 6/20 0.39
AURKA O14965 7/20 0.39
CDK4 P11802 5/20 0.39
TTK P33981 2/20 0.35
CDK1 P06493 2/20 0.34
INSR P06213 1/20 0.34
PDGFRB P09619 1/20 0.34
SRC P12931 1/20 0.34
PDGFRA P16234 1/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
CDK7 P50613 1/20 0.34
NTRK2 Q16620 1/20 0.34
HPGD P15428 2/20 0.32
GAA P10253 1/20 0.32
IDO1 P14902 1/20 0.31
AURKB Q96GD4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27033337 0.83 AURKA (0.41) AURKACDK4TTKCDK1INSR
SCHEMBL29639147 0.82 AURKA (0.47) AURKACDK4TTKCDK1INSR
SCHEMBL28767324 0.82 AURKA (0.47) AURKACDK4TTKCDK1INSR
SCHEMBL31756198 0.82 C5AR1 (0.31) C5AR1AURKACDK4
SCHEMBL31756128 0.82 C5AR1 (0.31) C5AR1AURKACDK4
SCHEMBL4202568 0.81 CDK4 (0.47) AURKACDK4TTKCDK1INSR
SCHEMBL20609704 0.77 AURKA (0.41) AURKACDK4TTKCDK1INSR
SCHEMBL31095262 0.77 GRM2 (0.41) AURKACDK4TTKCDK1INSR
SCHEMBL25209675 0.77 GRM2 (0.41) AURKACDK4TTKCDK1INSR
SCHEMBL25209677 0.77 GRM2 (0.41) AURKACDK4TTKCDK1INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF MERTK, ITK, CRKL C5AR1 955/4885AURKA 305/4885CDK4 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.